查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1529764

結締組織疾病市場規模、佔有率、趨勢分析報告：按疾病、藥物、分銷管道、地區和細分市場預測，2024-2030年

Connective Tissue Disease Market Size, Share & Trends Analysis Report By Disease (Rheumatoid Arthritis), By Drug (Pharmaceuticals), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

結締組織疾病市場趨勢

2023年，結締組織疾病的全球市場規模預計為240.4億美元，預計2024年至2030年複合年成長率為6.1%。這種成長是由於這些疾病的盛行率不斷增加、診斷技術和治療方法的進步以及對有效治療的需求不斷增加。類風濕性關節炎、全身性紅斑性狼瘡紅斑狼瘡和硬皮症自體免疫疾病和風濕性疾病的盛行率不斷上升，是結締組織疾病 (CTD) 市場成長的關鍵驅動力。根據美國的數據，大約 150 萬美國和超過 500 萬人患有某種形式的狼瘡。

此外，世界人口老化也是推動市場的因素之一。隨著年齡的成長，我們更有可能患上類風濕性關節炎和硬皮症等自體免疫疾病。這種人口趨勢正在推動對創新趨勢和個人化醫療的需求，以滿足患有結締組織疾病的老年患者的獨特需求。製藥公司正在投資研發工作，以推出針對這些疾病的新治療方法。

此外，精準醫學和生物標記發現的技術進步正在改變結締組織疾病的診斷和治療模式。旨在調節參與自體免疫反應的特定途徑的標靶治療的出現正在推動市場成長。例如，正在開發單株抗體等生物製藥，以靶向CTD發病機制中涉及的關鍵分子，為患者提供更有效、更安全的治療選擇。這些創新透過提供改善患者治療效果和生活品質的個人化解決方案正在再形成市場。

結締組織疾病全球市場區隔報告

該報告預測了全球、區域和國家層面的收益成長，並對2018年至2030年各子區隔的最新行業趨勢進行了分析。在這項研究中，Grand View Research 根據疾病、藥物、分銷管道和地區對全球結締組織病市場報告進行了細分：

  • 結締組織疾病展望（銷售，2018-2030）。
  • 類風濕性關節炎（RA）。
  • 全身性紅斑性狼瘡（SLE）。
  • 硬皮症。
  • 多發性肌炎。
  • 皮肌炎。
  • 修格蘭氏症候群。
  • 混合結締組織疾病（MCTD）。
  • 未分化結締組織疾病（UCTD）。
  • 其他結締組織疾病。
  • 結締組織疾病治療藥物展望（銷售額，2018-2030）。
  • 醫藥產品。

非類固醇消炎劑(NSAID)

緩解疾病抗風濕藥物 (DMARD)

皮質類固醇

其他藥品

  • 生物製藥

生技藥品

腫瘤壞死因子抑制劑

IL-6抑制劑

B細胞抑制劑

T細胞抑制劑

其他生技藥品

生物相似藥

  • 結締組織疾病通路展望（銷售額，2018-2030）。
  • 醫院藥房。
  • 零售藥房。
  • 網上藥局。
  • 區域展望（收益，2018-2030）。
  • 北美。

美國。

加拿大

墨西哥

  • 歐洲

英國

德國

法國

義大利

西班牙

丹麥

瑞典

挪威

  • 亞太地區

日本

中國

印度

澳洲

韓國

泰國

  • 拉丁美洲

巴西

阿根廷

  • 中東/非洲

南非

沙烏地阿拉伯

阿拉伯聯合大公國

科威特

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章結締組織疾病市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 結締組織疾病市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • 管道分析

第4章結締組織疾病市場：疾病估計與趨勢分析

  • 全球結締組織疾病市場：疾病儀表板
  • 全球結締組織疾病市場：疾病分析
  • 按疾病和收益的全球結締組織疾病市場
  • 類風濕性關節炎（RA）
  • 全身性紅斑性狼瘡（SLE）
  • 硬皮症
  • 多發性肌炎
  • 皮肌炎
  • 修格蘭氏症候群
  • 混合結締組織疾病 (MCTD)
  • 未分化結締組織疾病（UCTD）
  • 其他結締組織疾病

第5章結締組織疾病市場：藥品估計與趨勢分析

  • 全球結締組織疾病市場：製藥儀表板
  • 全球結締組織疾病市場：藥品波動分析
  • 按藥品分類的收益
  • 藥品
  • 生物製藥

5.5.2.2.1.1. 2018-2030 年 TNF 抑制劑市場估計與預測

5.5.2.3.1.1. 2018-2030 年 IL-6 抑制劑市場估計與預測

5.5.2.4.1.1. 2018-2030 年 B 細胞抑制劑市場估計與預測

5.5.2.5.1.1. 2018-2030 年 T 細胞抑制劑市場估計與預測

5.5.2.6.1.1. 2018-2030 年其他生技藥品市場估計與預測

  • 生物相似藥
    • 2018-2030 年生物相似藥市場估計與預測

第6章結締組織疾病市場：通路估計與趨勢分析

  • 全球結締組織疾病市場：分銷通路儀表板
  • 全球結締組織病市場：通路波動分析
  • 按分銷管道分類的收益
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第7章結締組織疾病市場：按疾病、藥物和分銷管道分類的區域估計和趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第8章 競爭格局

  • 公司/競爭對手分類
  • 供應商情況
    • List of key distributors and channel partners
    • Key customers
    • Key company market share analysis, 2023
    • AbbVie, Inc.
    • Amgen, Inc.
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • Johnson &Johnson Services, Inc.
    • Lily
    • Novartis AG
    • Pfizer Inc.
    • Regeneron Pharmaceuticals Inc.
    • UCB SA
Product Code: GVR-4-68040-348-8

Connective Tissue Disease Market Trends

The global connective tissue disease market size was estimated at USD 24.04 billion in 2023 and is expected to grow at a CAGR of 6.1% from 2024 to 2030. This growth is attributed to the increasing prevalence of these diseases, advancements in diagnostic techniques & treatment approaches, and growing demand for effective treatments. The rising incidence of autoimmune and rheumatic disorders, such as rheumatoid arthritis, systemic lupus erythematosus, and scleroderma, is a significant driver for the growth of the connective tissue disease (CTD) market. According to the Lupus Foundation of America,about 1.5 million Americans and more than five million people globally are affected by some type of lupus.

Moreover, the aging population worldwide is another significant driver for the growth of the market. As individuals age, they are more prone to developing autoimmune disorders such as rheumatoid arthritis and scleroderma, both of which fall under the category of connective tissue disease. This demographic trend fuels the demand for innovative therapies and personalized medicine approaches tailored to address the specific needs of elderly patients with connective tissue diseases. Pharmaceutical companies invest in research and development activities to introduce novel treatments targeting these conditions.

Furthermore, technological advancements in precision medicine and biomarker discovery are revolutionizing the diagnosis and treatment landscape for connective tissue diseases. The emergence of targeted therapies that aim to modulate specific pathways involved in autoimmune responses is propelling market growth. For instance, biologics such as monoclonal antibodies are being developed to target key molecules implicated in CTD pathogenesis, offering patients more effective and safer treatment options. These innovations are reshaping the market by providing personalized solutions that improve patient outcomes and quality of life.

Global Connective Tissue Disease Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global connective tissue disease market report on the basis of disease, drug, distribution channel, region:

  • Connective Tissue Disease Outlook (Revenue, USD Million, 2018 - 2030)
  • Rheumatoid Arthritis (RA)
  • Systemic Lupus Erythematosus (SLE)
  • Scleroderma
  • Polymyositis
  • Dermatomyositis
  • Sjogren's Syndrome
  • Mixed Connective Tissue Disease (MCTD)
  • Undifferentiated Connective Tissue Disease (UCTD)
  • Other connective tissue disease
  • Connective Tissue Disease Drug Outlook (Revenue, USD Million, 2018 - 2030)
  • Pharmaceuticals

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

Corticosteroids

Other Pharmaceuticals

  • Biopharmaceuticals

Biologics

TNF Inhibitors

IL-6 Inhibitors

B-cell Inhibitors

T-cell Inhibitors

Other Biologics

Biosimilars

  • Connective Tissue Disease Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Regional Outlook (Revenue, USD Million, 2018 - 2030)
  • North America

U.S.

Canada

Mexico

  • Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

  • Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

  • Latin America

Brazil

Argentina

  • Middle East and Africa

South Africa

Saudi Arabia

UAE

Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease
    • 1.2.2. Drug
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Disease outlook
    • 2.2.2. Drug outlook
    • 2.2.3. Distribution Channel outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Connective Tissue Disease Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of connective tissue diseases
      • 3.2.1.2. Aging Population
      • 3.2.1.3. Technological advancements
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High treatment cost
  • 3.3. Connective Tissue Disease Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pipeline Analysis

Chapter 4. Connective Tissue Disease Market: Disease Estimates & Trend Analysis

  • 4.1. Global Connective Tissue Disease Market: Disease Dashboard
  • 4.2. Global Connective Tissue Disease Market: Disease Analysis
  • 4.3. Global Connective Tissue Disease Market by Disease, Revenue
  • 4.4. Rheumatoid Arthritis (RA)
    • 4.4.1. Rheumatoid Arthritis (RA) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Systemic Lupus Erythematosus (SLE)
    • 4.5.1. Systemic Lupus Erythematosus (SLE) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Scleroderma
    • 4.6.1. Scleroderma market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Polymyositis
    • 4.7.1. Polymyositis market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Dermatomyositis
    • 4.8.1. Dermatomyositis market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. Sjogren's Syndrome
    • 4.9.1. Postpartum psychosis market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10. Mixed Connective Tissue Disease (MCTD)
    • 4.10.1. Mixed Connective Tissue Disease (MCTD) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.11. Undifferentiated Connective Tissue Disease (UCTD)
    • 4.11.1. Undifferentiated Connective Tissue Disease (UCTD) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.12. Other connective tissue disease
    • 4.12.1. Other connective tissue disease market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Connective Tissue Disease Market: Drug Estimates & Trend Analysis

  • 5.1. Global Connective Tissue Disease Market: Drug Dashboard
  • 5.2. Global Connective Tissue Disease Market: Drug Movement Analysis
  • 5.3. Global Connective Tissue Disease Market Estimates and Forecasts, By Drug, Revenue (USD Million)
  • 5.4. Pharmaceuticals
    • 5.4.1. Pharmaceuticals market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
      • 5.4.2.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
      • 5.4.3.1. Disease-Modifying Anti-Rheumatic Drugs (DMARDs) market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Corticosteroids
      • 5.4.4.1. Corticosteroids market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5. Other Pharmaceuticals
      • 5.4.5.1. Other Pharmaceuticals market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Biopharmaceuticals
    • 5.5.1. Biopharmaceuticals market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.2. Biologics
      • 5.5.2.1. Biologics market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.5.2.2. TNF Inhibitors

5.5.2.2.1.1. TNF Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)

      • 5.5.2.3. IL-6 Inhibitors

5.5.2.3.1.1. IL-6 Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)

      • 5.5.2.4. B-cell Inhibitors

5.5.2.4.1.1. B-cell Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)

      • 5.5.2.5. T-cell inhibitors

5.5.2.5.1.1. T-cell Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)

      • 5.5.2.6. Other Biologics

5.5.2.6.1.1. Other Biologics market estimates and forecasts 2018 to 2030 (USD Million)

  • 5.6. Biosimilars
    • 5.6.1. Biosimilars market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Connective Tissue Disease Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Global Connective Tissue Disease Market: Distribution Channel Dashboard
  • 6.2. Global Connective Tissue Disease Market: Distribution Channel Movement Analysis
  • 6.3. Global Connective Tissue Disease Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Online Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Connective Tissue Disease Market: Regional Estimates & Trend Analysis by Disease, Drug, and Distribution Channel

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Vendor Landscape
    • 8.2.1. List of key distributors and channel partners
    • 8.2.2. Key customers
    • 8.2.3. Key company market share analysis, 2023
    • 8.2.4. AbbVie, Inc.
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Amgen, Inc.
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. Boehringer Ingelheim International GmbH
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Bristol-Myers Squibb Company
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. F. Hoffmann-La Roche Ltd.
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. Johnson & Johnson Services, Inc.
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. Lily
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Product benchmarking
      • 8.2.10.4. Strategic initiatives
    • 8.2.11. Novartis AG
      • 8.2.11.1. Company overview
      • 8.2.11.2. Financial performance
      • 8.2.11.3. Product benchmarking
      • 8.2.11.4. Strategic initiatives
    • 8.2.12. Pfizer Inc.
      • 8.2.12.1. Company overview
      • 8.2.12.2. Financial performance
      • 8.2.12.3. Product benchmarking
      • 8.2.12.4. Strategic initiatives
    • 8.2.13. Regeneron Pharmaceuticals Inc.
      • 8.2.13.1. Company overview
      • 8.2.13.2. Financial performance
      • 8.2.13.3. Product benchmarking
      • 8.2.13.4. Strategic initiatives
    • 8.2.14. UCB S.A.
      • 8.2.14.1. Company overview
      • 8.2.14.2. Financial performance
      • 8.2.14.3. Product benchmarking
      • 8.2.14.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Connective Tissue Disease market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 4 North America Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 5 North America Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 U.S. Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 7 U.S. Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 8 U.S. Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 9 Canada Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 10 Canada Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 11 Canada Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 12 Mexico Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 13 Mexico Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 14 Mexico Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 15 Europe Connective Tissue Disease market, by region, 2018 - 2030 (USD Million)
  • Table 16 Europe Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 17 Europe Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 18 Europe Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 19 Germany Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 20 Germany Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 21 Germany Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 22 UK Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 23 UK Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 24 UK Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25 France Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 26 France Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 27 France Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 Italy Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 29 Italy Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 30 Italy Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 31 Spain Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 32 Spain Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 33 Spain Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34 Denmark Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 35 Denmark Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 36 Denmark Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 Sweden Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 38 Sweden Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 39 Sweden Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 40 Norway Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 41 Norway Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 42 Norway Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Connective Tissue Disease market, by region, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 47 China Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 48 China Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 49 China Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 50 Japan Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 51 Japan Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 52 Japan Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 53 India Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 54 India Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 55 India Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 56 South Korea Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 57 South Korea Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 58 South Korea Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 59 Australia Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 60 Australia Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 61 Australia Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62 Thailand Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 63 Thailand Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 64 Thailand Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 65 Latin America Connective Tissue Disease market, by region, 2018 - 2030 (USD Million)
  • Table 66 Latin America Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 67 Latin America Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 68 Latin America Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 69 Brazil Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 70 Brazil Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 71 Brazil Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 72 Argentina Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 73 Argentina Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 74 Argentina Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 75 MEA Connective Tissue Disease market, by region, 2018 - 2030 (USD Million)
  • Table 76 MEA Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 77 MEA Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 78 MEA Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 79 South Africa Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 80 South Africa Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 81 South Africa Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 85 UAE Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 86 UAE Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 87 UAE Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 88 Kuwait Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 89 Kuwait Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 90 Kuwait Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Connective Tissue Disease market: market outlook
  • Fig. 14 Connective Tissue Disease competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Connective Tissue Disease market driver impact
  • Fig. 18 Connective Tissue Disease market restraint impact
  • Fig. 19 Connective Tissue Disease market: Disease movement analysis
  • Fig. 20 Connective Tissue Disease market: Disease outlook and key takeaways
  • Fig. 21 Rheumatoid Arthritis (RA) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Systemic Lupus Erythematosus (SLE) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Scleroderma market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Polymyositis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Dermatomyositis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Sjogren's Syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Mixed Connective Tissue Disease (MCTD) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Undifferentiated Connective Tissue Disease (UCTD) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Other connective tissue diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Connective Tissue Disease market: Drug movement analysis
  • Fig. 31 Connective Tissue Disease market: Drug outlook and key takeaways
  • Fig. 32 Pharmaceuticals market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Disease-Modifying Anti-Rheumatic Drugs (DMARDs) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Corticosteroids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Biopharmaceuticals market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Biologics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 TNF Inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 IL-6 Inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 B-cell Inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 T-cell Inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Other Biologics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Biosimilars market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 Connective Tissue Disease market: Distribution channel movement analysis
  • Fig. 46 Connective Tissue Disease market: Distribution channel outlook and key takeaways
  • Fig. 47 Hospital Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Retail Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Online Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Global Connective Tissue Disease market: Regional movement analysis
  • Fig. 51 Global Connective Tissue Disease market: Regional outlook and key takeaways
  • Fig. 52 Global Connective Tissue Disease market share and leading players
  • Fig. 53 North America, by country
  • Fig. 54 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 U.S. key country dynamics
  • Fig. 56 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Canada key country dynamics
  • Fig. 58 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Mexico key country dynamics
  • Fig. 60 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 UK key country dynamics
  • Fig. 63 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Germany key country dynamics
  • Fig. 65 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 France key country dynamics
  • Fig. 67 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Italy key country dynamics
  • Fig. 69 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Spain key country dynamics
  • Fig. 71 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Denmark key country dynamics
  • Fig. 73 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Sweden key country dynamics
  • Fig. 75 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Norway key country dynamics
  • Fig. 77 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 China key country dynamics
  • Fig. 80 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Japan key country dynamics
  • Fig. 82 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 India key country dynamics
  • Fig. 84 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Thailand key country dynamics
  • Fig. 86 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 South Korea key country dynamics
  • Fig. 88 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Australia key country dynamics
  • Fig. 90 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Brazil key country dynamics
  • Fig. 93 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Argentina key country dynamics
  • Fig. 95 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 96 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 South Africa key country dynamics
  • Fig. 98 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Saudi Arabia key country dynamics
  • Fig. 100 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 101 UAE key country dynamics
  • Fig. 102 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Kuwait key country dynamics
  • Fig. 104 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 105 Market share of key market players - Connective Tissue Disease market